Lynozyfic

Active Ingredient(s): Linvoseltamab-gcpt
FDA Approved: * July 2, 2025
Pharm Company: * RENGENERON PHARMACEUTICALS, INC.
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lynozyfic 5 mg/2.5ml Intravenous Injection, Solution, Concentrate
NDC: 61755-054
Labeler:
Regeneron Pharmaceuticals, Inc.
Lynozyfic 200 mg/10ml Intravenous Injection, Solution, Concentrate
NDC: 61755-056
Labeler:
Regeneron Pharmaceuticals, Inc.